Biogen reports positive phase 2 results for lupus skin drug

March 28, 2026 3:00 PM

Biogen Inc. (NASDAQ: BIIB) announced positive results from the phase 2 portion of its AMETHYST study evaluating litifilimab for cutaneous ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found